Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1103/physreva.50.4422 | DOI Listing |
Am J Cardiovasc Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Flurpiridaz F 18 (FLYRCADO™) is an intravenous (IV) radioactive diagnostic drug being developed by GE Healthcare and Lantheus Medical Imaging for use in positron emission tomography (PET) myocardial perfusion imaging (MPI) to detect coronary artery disease (CAD). In September 2024, flurpiridaz F 18 was approved in the USA for PET MPI under rest or stress (pharmacologic or exercise) in adult patients with known or suspected CAD to evaluate for myocardial ischemia and infarction. This article summarizes the milestones in the development of flurpiridaz F 18 leading to this first approval for use in PET MPI in adult patients to evaluate for myocardial ischemia and infarction.
View Article and Find Full Text PDFDiagnostics (Basel)
January 2025
Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2000, Australia.
We appreciate the interest of Troisi and his colleagues [...
View Article and Find Full Text PDFDiagnostics (Basel)
January 2025
Ophthalmologic Unit, Salerno Hospital University, 84100 Salerno, Italy.
We read with great interest the recent article by Cabrera-Aguas M [...
View Article and Find Full Text PDFAn analysis of the methodology used by the authors of the commented article is presented and errors related to data preparation are pointed out.
View Article and Find Full Text PDFAJR Am J Roentgenol
January 2025
Brown Radiology Human Factors Lab, Department of Diagnostic Imaging, Warren Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!